Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation botulinumtoxinA (RelabotulinumtoxinA) for the Treatment of Glabellar Lines (frown) and Lateral Canthal Lines (crow's Feet)

Both studies met their primary endpoints with significantly higher response than placebo after one month for both frown lines and crow's feet Results showed rapid onset of action with median

Related Keywords

,Christian Marcoux ,Kostenloser Wertpapierhandel ,Baldo Scassellati Sforzolini ,Rachel Mooney ,Las Vegas ,Liljegren Sundberg ,Global Head Of Research Development ,Corporate Communications ,Ready Relabotulinumtoxin Aesthetic Development Stud ,Global Franchise Communications ,Vegas Cosmetic Surgery Aesthetic Dermatology ,Aesthetic Development Study ,Scassellati Sforzolini ,Research Development ,Injectable Aesthetics ,Communications Officer ,Franchise Communications ,Communications Director ,Galderma ,Nnounces ,Positive ,Results ,Hase ,Studies ,Novel ,Liquid ,Formulation ,Otulinumtoxina ,Elabotulinumtoxina ,Treatment ,Labellar ,Fines ,Rown ,Bilateral ,Santhal ,Row ,Feet ,